MX389762B - Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp). - Google Patents

Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp).

Info

Publication number
MX389762B
MX389762B MX2016011827A MX2016011827A MX389762B MX 389762 B MX389762 B MX 389762B MX 2016011827 A MX2016011827 A MX 2016011827A MX 2016011827 A MX2016011827 A MX 2016011827A MX 389762 B MX389762 B MX 389762B
Authority
MX
Mexico
Prior art keywords
iapp
amyloid polypeptide
islet amyloid
glucose tolerance
impaired glucose
Prior art date
Application number
MX2016011827A
Other languages
English (en)
Other versions
MX2016011827A (es
Inventor
Fabian Wirth
Fabrice Heitz
Jan Grimm
Tobias Welt
Original Assignee
Neurimmune Holding Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag, Univ Zuerich filed Critical Neurimmune Holding Ag
Publication of MX2016011827A publication Critical patent/MX2016011827A/es
Publication of MX389762B publication Critical patent/MX389762B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)

Abstract

La presente invención se refiere a una composición para expandir in vitro linfocitos caracterizada porque comprende interleucina 2 (IL-2), interleucina 15 (IL-15) e interleucina 21 (IL-21), en donde la composición está en forma líquida, la concentración de IL-2 en la composición líquida está en el intervalo de 500 a 2000 U/ml, la concentración de IL-15 está en el intervalo de 0.1 a 100 ng/ml y en donde la concentración de IL-21 está en el intervalo de 0.1 a 100 ng/ml. Un método para preparar una población clínicamente relevante, una población de linfocitos obtenidos por el método para preparar dicha población de linfocitos y una composición de linfocitos.
MX2016011827A 2014-03-12 2015-03-12 Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp). MX389762B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14159194 2014-03-12
PCT/EP2015/055238 WO2015136055A1 (en) 2014-03-12 2015-03-12 Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose tolerance

Publications (2)

Publication Number Publication Date
MX2016011827A MX2016011827A (es) 2017-04-27
MX389762B true MX389762B (es) 2025-03-20

Family

ID=50272417

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011827A MX389762B (es) 2014-03-12 2015-03-12 Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp).
MX2022001090A MX2022001090A (es) 2014-03-12 2016-09-12 Novedosos compuestos capaces de antagonizar el daño a las células-beta y la tolerancia deteriorada a la glucosa inducidos por el polipéptido amiloide de los islotes (iapp).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001090A MX2022001090A (es) 2014-03-12 2016-09-12 Novedosos compuestos capaces de antagonizar el daño a las células-beta y la tolerancia deteriorada a la glucosa inducidos por el polipéptido amiloide de los islotes (iapp).

Country Status (12)

Country Link
US (3) US10544213B2 (es)
EP (1) EP3116306A1 (es)
JP (1) JP6556160B2 (es)
KR (1) KR102342087B1 (es)
CN (1) CN106536552A (es)
AU (1) AU2015228818B2 (es)
BR (1) BR112016021036A2 (es)
CA (1) CA2942120A1 (es)
EA (1) EA039745B1 (es)
IL (1) IL247737B (es)
MX (2) MX389762B (es)
WO (1) WO2015136055A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
WO2003092619A2 (en) * 2002-04-30 2003-11-13 Wyeth Holdings Corporation Prevention and treatment of type 2 diabetes
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2011151833A1 (en) * 2010-06-03 2011-12-08 Ramot At Tel-Aviv University Ltd. Methods of treating diabetes and compositions capable of same
WO2012170977A1 (en) * 2011-06-10 2012-12-13 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
DK2895512T3 (en) * 2012-09-12 2018-10-15 Neurimmune Holding Ag Antibodies specific for human islet amyloid polypeptide (HIAPP) and uses thereof
WO2015004632A1 (en) * 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp

Also Published As

Publication number Publication date
CN106536552A (zh) 2017-03-22
WO2015136055A1 (en) 2015-09-17
JP6556160B2 (ja) 2019-08-07
EA201691708A1 (ru) 2017-03-31
KR102342087B1 (ko) 2021-12-27
CA2942120A1 (en) 2015-09-17
JP2017510571A (ja) 2017-04-13
MX2016011827A (es) 2017-04-27
AU2015228818B2 (en) 2021-02-11
IL247737B (en) 2020-09-30
BR112016021036A2 (pt) 2021-06-22
IL247737A0 (en) 2016-11-30
MX2022001090A (es) 2022-02-14
EA039745B1 (ru) 2022-03-05
AU2015228818A1 (en) 2016-10-20
US10544213B2 (en) 2020-01-28
US20200231667A1 (en) 2020-07-23
US20180179276A1 (en) 2018-06-28
KR20160127133A (ko) 2016-11-02
US20230287106A1 (en) 2023-09-14
AU2015228818A8 (en) 2020-10-22
EP3116306A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
CO2017012974A2 (es) Anticuerpos de unión a tau
BR112018000769A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos
CO2017012971A2 (es) Anticuerpos de unión a tau
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
MX385679B (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
MX2017001285A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112016023607A2 (pt) uso médico de compostos de artemisinina e agonistas de gefirina
EP4268843A3 (en) Improved il-6 antibodies
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
MX387454B (es) DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
MX2016004325A (es) Nuevo derivado de un analogo de insulina.
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
CO2018010286A2 (es) Método para la purificación de proteínas
CO6680692A2 (es) Método y composición para producir azúcar clarificada
WO2015083125A3 (en) Anti-islet-amyloid-polypeptide (iaap) kcntatcatq antibodies
MX389762B (es) Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp).
CL2017001633A1 (es) Método de manufactura de proteína.
DK3574912T3 (da) Sammensætning til behandling af diabetisk sygdom